Cisplatin Effects in Lung Adenocarcinoma-bearing Mice, Alone and in Combination with Erlotinib | Zendy

Cierra N. Sharp | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Cisplatin Effects in Lung Adenocarcinoma-bearing Mice, Alone and in Combination with Erlotinib

Author(s) -

Cierra N. Sharp

Publication year - 2018

Publication title -

toxicologic pathology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.613

H-Index - 108

eISSN - 1533-1601

pISSN - 0192-6233

DOI - 10.1177/0192623318798342

Subject(s) - cisplatin , nephrotoxicity , medicine , kidney disease , erlotinib , lung , adenocarcinoma , pharmacology , regimen , kidney , lung cancer , acute kidney injury , chemotherapy , oncology , cancer , epidermal growth factor receptor

Cisplatin causes nephrotoxicity that can lead to the development of acute kidney injury or chronic kidney disease. However, the current mouse model of cisplatin nephrotoxicity is neither physiologically nor clinically relevant. Our goal was to improve upon these deficits by developing a repeated, low-dose regimen of cisplatin and combining it with a transgenic mouse model of lung adenocarcinoma. This overview details how addressing these deficits have improved our understanding of cisplatin-induced kidney injury.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research